148 related articles for article (PubMed ID: 17103382)
1. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.
Natrajan R; Little SE; Sodha N; Reis-Filho JS; Mackay A; Fenwick K; Ashworth A; Perlman EJ; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
J Pathol; 2007 Jan; 211(1):52-9. PubMed ID: 17103382
[TBL] [Abstract][Full Text] [Related]
2. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.
Natrajan R; Williams RD; Hing SN; Mackay A; Reis-Filho JS; Fenwick K; Iravani M; Valgeirsson H; Grigoriadis A; Langford CF; Dovey O; Gregory SG; Weber BL; Ashworth A; Grundy PE; Pritchard-Jones K; Jones C
J Pathol; 2006 Sep; 210(1):49-58. PubMed ID: 16823893
[TBL] [Abstract][Full Text] [Related]
3. Raised risk of Wilms tumour in patients with aniridia and submicroscopic WT1 deletion.
van Heyningen V; Hoovers JM; de Kraker J; Crolla JA
J Med Genet; 2007 Dec; 44(12):787-90. PubMed ID: 17630404
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
Williams RD; Al-Saadi R; Natrajan R; Mackay A; Chagtai T; Little S; Hing SN; Fenwick K; Ashworth A; Grundy P; Anderson JR; Dome JS; Perlman EJ; Jones C; Pritchard-Jones K
Genes Chromosomes Cancer; 2011 Dec; 50(12):982-95. PubMed ID: 21882282
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
Cheah PL; Looi LM; Chan LL
Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
[TBL] [Abstract][Full Text] [Related]
7. Constitutional and somatic mutations in the WT1 gene in Wilms' tumor patients.
Nordenskjöld A; Friedman E; Sandstedt B; Söderhäll S; Anvret M
Int J Cancer; 1995 Nov; 63(4):516-22. PubMed ID: 7591260
[TBL] [Abstract][Full Text] [Related]
8. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
9. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors.
Kaneko Y; Homma C; Maseki N; Sakurai M; Hata J
Cancer Res; 1991 Nov; 51(21):5937-42. PubMed ID: 1657374
[TBL] [Abstract][Full Text] [Related]
10. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of the remaining allele of the WT1 gene in a Wilms' tumour from a WAGR patient.
Brown KW; Watson JE; Poirier V; Mott MG; Berry PJ; Maitland NJ
Oncogene; 1992 Apr; 7(4):763-8. PubMed ID: 1314370
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of chromosome 11p imbalances in aniridia and Wilms tumor patients.
Busch M; Leube B; Thiel A; Schanze I; Beier M; Royer-Pokora B
Am J Med Genet A; 2013 May; 161A(5):958-64. PubMed ID: 23494989
[TBL] [Abstract][Full Text] [Related]
13. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
Pritchard-Jones K; Fleming S
Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
[TBL] [Abstract][Full Text] [Related]
14. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.
Hing S; Lu YJ; Summersgill B; King-Underwood L; Nicholson J; Grundy P; Grundy R; Gessler M; Shipley J; Pritchard-Jones K
Am J Pathol; 2001 Feb; 158(2):393-8. PubMed ID: 11159177
[TBL] [Abstract][Full Text] [Related]
15. Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse.
Natrajan R; Reis-Filho JS; Little SE; Messahel B; Brundler MA; Dome JS; Grundy PE; Vujanic GM; Pritchard-Jones K; Jones C
Cancer Res; 2006 Dec; 66(23):11148-55. PubMed ID: 17145858
[TBL] [Abstract][Full Text] [Related]
16. 11p13 deletion, Wilms' tumour, and aniridia: unusual genetic, non-ocular and ocular features of three cases.
Jotterand V; Boisjoly HM; Harnois C; Bigonesse P; Laframboise R; Gagné R; St-Pierre A
Br J Ophthalmol; 1990 Sep; 74(9):568-70. PubMed ID: 2168204
[TBL] [Abstract][Full Text] [Related]
17. The T-ALL specific t(11;14)(p13;q11) translocation breakpoint cluster region is located near to the Wilms' tumour predisposition locus.
Boehm T; Lavenir I; Forster A; Wadey RB; Cowell JK; Harbott J; Lampert F; Waters J; Sherrington P; Couillin P
Oncogene; 1988 Dec; 3(6):691-5. PubMed ID: 2577871
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetics and molecular genetics of Wilms' tumor of childhood.
Slater RM; Mannens MM
Cancer Genet Cytogenet; 1992 Jul; 61(2):111-21. PubMed ID: 1322233
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity at 11p13 in Wilms' tumours does not necessarily involve mutations in the WT1 gene.
Cowell JK; Groves N; Baird P
Br J Cancer; 1993 Jun; 67(6):1259-61. PubMed ID: 8390282
[TBL] [Abstract][Full Text] [Related]
20. A nude mouse Wilms' tumor line (KCMC-WT-1) derived from an aniridia patient with monoalleleic partial deletion of chromosome 11p.
Nagashima Y; Nishihira H; Miyagi Y; Tanaka Y; Sasaki Y; Nishi T; Imaizumi K; Aoki I; Misugi K
Cancer; 1996 Feb; 77(4):799-804. PubMed ID: 8616775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
